Who is sponsoring NCT02513004?

NCT02513004 is sponsored by Yongjian Wu.

What condition does NCT02513004 study?

NCT02513004 studies Coronary Disease.

What drugs are being tested in NCT02513004?

Interventions: Ticagrelor, Clopidogrel.

What is the status of NCT02513004?

NCT02513004 is currently UNKNOWN.

Last reviewed 2017-02-08 · How we verify

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing "One-stop" Hybrid Coronary Revascularization

NCT02513004 Phase 4 UNKNOWN

This study is designed to test the hypothesis that the onset of the antiplatelet effect 90mg-first-dose of ticagrelor will be more rapid and greater than 300mg-loading-dose of clopidogrel evaluated by P2Y12 reaction units measured by Verify NowTM P2Y12 assay at 1 hour in patients undergoing one-stop Hybrid coronary revascularization(HCR).

Details

Lead sponsor	Yongjian Wu
Phase	Phase 4
Status	UNKNOWN
Enrolment	60
Start date	2015-06
Completion	2017-04

Conditions

Coronary Disease

Interventions

Ticagrelor
Clopidogrel

Primary outcomes

1hourPRU — 1hour
PRU measured by Verify NowTM P2Y12 assay at 1 hour after first dose of study drug administered as powder via a nasogastric tube after conﬁrmation of LIMA-LAD graft patency during the HCR procedure in HCR patients.

Countries

China